| Thomas E. Shenk To Retire From Merck's Board of Directors |
PharmiWeb.com (press release)Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Thomas E. Shenk, Ph.D., has decided to retire from its board of directors, effective today. Dr. Shenk is leaving the board to focus on the new company he is ...
|
| Tamara Cansler to be Honored with Sixth Annual Rebecca Lukens Award |
PR Web (press release)She found such a position at Merck Pharmaceuticals in West Point, PA. She was trained as an Industrial Engineer. It was quite a change from teaching sonnets to sixth graders. “Merck had an unusual business philosophy,” says Tammy.
|
| Merck and Threshold Announce Development of Phase III Hypoxia-Targeted Drug TH-302 |
Korea IT Times (press release)DARMSTADT, GERMANY- Today Merck KGaA announced that a global agreement was signed with Threshold Pharmaceuticals, Inc. in San Francisco. This agreement co-developed and commercialized TH-302, Threshold's small molecule hypoxia-targeted drug.
|
| Elix technology ensures pure water quality |
Laboratory TalkMerck Millipore, the Life Science division of Merck, has announced the addition of its Elix Essential systems to the company's existing range of Elix water purification equipment. The new systems integrate patented Elix electrodeionisation (EDI) ...
|
| Thomas E. Shenk To Retire From Merck's Board of Directors |
EON: Enhanced Online News (press release)WHITEHOUSE STATION, NJ--(EON: Enhanced Online News)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Thomas E. Shenk, Ph.D., has decided to retire from its board of directors, effective today.
|
| Modified Study, Same Bloody Results |
DailyFinanceBy Brian Orelli, PhD, The Motley Fool Posted 8:39PM 02/08/12 Investing When Merck (NYS: MRK) received bad news last year about its blood thinner vorapaxar, it stopped one trial and modified another because it was clear that patients who had previously ...
|
| Modified Study, Same Bloody Results |
Motley FoolBy Brian Orelli, PhD | More Articles When Merck (NYSE: MRK ) received bad news last year about its blood thinner vorapaxar, it stopped one trial and modified another because it was clear that patients who had previously had strokes were more likely to ...
|
